Company news
Spero Therapeutics, Inc. (NASDAQ:SPRO) news
Spero Therapeutics, Inc. news releases on 6ix. Latest, Oct 2, 2026: Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 2, 2026
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
August 12, 2026
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
August 4, 2026
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
July 27, 2026
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
July 14, 2026
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
July 14, 2026
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
July 14, 2026
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
June 17, 2026
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
May 13, 2026
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
March 25, 2026
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
March 18, 2026
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
December 19, 2025
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 28, 2025
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
November 13, 2025
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
November 4, 2025
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
October 21, 2025
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek
October 14, 2025
Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer
September 4, 2025
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update
August 12, 2025
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025
August 5, 2025
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
May 28, 2025
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update
May 13, 2025
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
April 28, 2025
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update
March 27, 2025
Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025
March 18, 2025
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
February 25, 2025
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
February 25, 2025
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
January 9, 2025
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
November 13, 2024
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
October 28, 2024
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
October 15, 2024
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
October 1, 2024
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
August 4, 2024
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
May 14, 2024
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2024
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
March 12, 2024
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
March 5, 2024
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
February 27, 2024
Spero Therapeutics Provides Corporate Update and 2024 Outlook
January 4, 2024
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
January 1, 2024
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
November 12, 2023
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
November 5, 2023
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
October 31, 2023
Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update
August 9, 2023
Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr
July 30, 2023
Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer
June 13, 2023
Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update
May 10, 2023
Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
May 3, 2023